Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Accretion NutravedaBOM:544694 21 OCF Margin % is -117.91% as of Mar. 2026. GuruFocus rates BOM:544694 with a GF Score™ of 21/100. The stock has 3 warning signs investors should review. Among 964 Drug Manufacturers companies, Accretion Nutraveda ranks worse than 91.29% on this metric.
The historical rank and industry rank for Accretion Nutraveda's OCF Margin % or its related term are showing as below:
BOM:544694'
s OCF Margin % Range Over the Past 10 Years
Min: -71.2 Med: -4.86 Max: 23.47
Current: -71.2
During the past 4 years, the highest OCF Margin % of Accretion Nutraveda was 23.47%. The lowest was -71.20%. And the median was -4.86%.
BOM:544694's OCF Margin % is ranked worse than 91.29% of 964
companies
in the Drug Manufacturers industry
Industry Median: 10.035
vs BOM:544694: -71.20
The historical data trend for Accretion Nutraveda's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Accretion Nutraveda OCF Margin % Chart
Accretion Nutraveda Annual Data
Trend
Mar23
Mar24
Mar25
Mar26
OCF Margin %
23.47
4.60
-14.32
-71.20
Accretion Nutraveda Semi-Annual Data
Mar23
Mar24
Mar25
Sep25
Mar26
OCF Margin %
0.00
0.00
0.00
-6.31
-117.91
BOM:544694 vs ZTS: OCF Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Accretion Nutraveda's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Accretion Nutraveda OCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Accretion Nutraveda's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Accretion Nutraveda's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Accretion Nutraveda (BOM:544694) has a OCF Margin % of -117.91% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Accretion Nutraveda and its competitors. According to the industry distribution chart, Accretion Nutraveda ranks #880 out of 964 companies in the Drug Manufacturers industry, placing it in the top 91.3%.
Is Accretion Nutraveda's OCF Margin % too high?
Accretion Nutraveda's current OCF Margin % is -117.91%. Based on the distribution chart, Accretion Nutraveda ranks #880 out of 964 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Accretion Nutraveda has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Accretion Nutraveda's OCF Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Accretion Nutraveda ranks #880 out of 964 companies for OCF Margin %. This places Accretion Nutraveda in the lower half of its industry. The industry median OCF Margin % is 10.04. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Drug Manufacturers company?
The median OCF Margin % among Drug Manufacturers companies is 10.04, based on 964 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Accretion Nutraveda and its competitors. For the Drug Manufacturers industry, the median OCF Margin % is 10.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Accretion Nutraveda's current OCF Margin % is -117.91%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Accretion Nutraveda stock overvalued right now?
Accretion Nutraveda (BOM:544694) has a current OCF Margin % of -117.91%. The current OCF Margin % is -117.91%. Accretion Nutraveda's overall GF Score™ is 21/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Accretion Nutraveda (BOM:544694), the current OCF Margin % is -117.91% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Accretion Nutraveda Ltd is engaged in the business of the Manufacturing of Ayurvedic and Nutraceutical products across several dosage forms, including Tablets, Capsules, Oral liquids, Oral Powders, External Preparation and Oils. It is a healthcare focused Company specializing in contract manufacturing, serving domestic as well as export markets in various countries like Sri Lanka, Singapore and the USA. The company offers a diverse range of dosage forms, leveraging both Classical Ayurvedic principles and modern nutraceutical science. Its product portfolio includes Tablets, such as film-coated and chewable varieties, for applications in liver care, gynecological care, bone and joint health, and respiratory support.
21GF Score
Get the complete analysis for BOM:544694
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:544694 has been successfully added to your 
